X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

Content Team by Content Team
19th January 2021
in Drug Development, News
KORSCH AND MEDELPHARM Partner to Introduce R&D Equipment Portfolio

KORSCH AG – the global leader in tablet press technology, offering solutions for product development, scale-up, high-speed production, multi-layer, mini-tablet, and WIP/high-containment applications – has announced a strategic partnership with MEDELPHARM, the global leader in the development of compaction simulator technology, to introduce a new portfolio of equipment geared to R&D-stage production. The collaboration includes a joint microsite dedicated to the new R&D lineup.

Leveraging the companies’ combined 135-plus years of experience with small-scale, fully instrumented machines, the R&D product portfolio addresses and overcomes longstanding challenges, from early stage powder characterization and formulation development to scale-up and production support.?The combined KORSCH-MEDELPHARM R&D product equipment lineup includes:

XP 1: Robust single-punch tablet press with small batch capabilities
STYL’One Nano:Benchtop compaction simulator with integrated analytical software, for single layer formulation development
STYL’One Evo:Advanced compaction simulator with integrated analytical software and multi-layer capability, allowing R&D at production speed
XL 100:Small-scale rotary press for product development and clinical batch production

Covering the full spectrum of tableting technology from single-layer to five-layer as well as core coating capabilities, the new R&D product equipment portfolio serves as a versatile complement to KORSCH’s multi-layer production machinery. Notably, the STYL’One Evo offers the ability to simulate all high-speed production presses to predict product performance with minimal material quantities.

Like the MEDELPHARM Science Laboratory in Lyon, France, the KORSCH Innovation Centers in Berlin and Boston have installed the STYL’One Evo and STYL’One Nano machines for demonstration, testing and, by simulating the full range of KORSCH production equipment, product trials with predictive results. The facilities in Lyon and Berlin also are offering contract services including formulation optimization, powder analysis, and material characterization.

MEDELPHARM is the designer and proprietor of STYL’One hardware and software technology. Under the agreement, MEDELPHARM equipment and software will continue to be designed, developed, and manufactured in Lyon, France. With an existing global customer base of nearly 200 machines, MEDELPHARM STYL’One technology will be supported by the KORSCH global technical service network with OEM spare part inventories in Berlin and Boston.

To support worldwide distribution, KORSCH will offer the fully combined R&D product equipment lineup on a global basis with the exception of France and Belgium. In those countries, MEDELPHARM has exclusive rights to distribute the new line, as well as the full range of KORSCH production equipment, in addition to its current representation of LB Bohle and other complementary technology brands.

About KORSCH AG

Founded in 1919 in Berlin, Germany, KORSCH AG has a 100-year tradition and commitment to innovation. As the only true specialist in the tablet press market, KORSCH focuses solely and completely on the advancement of tablet press technology for pharmaceutical, nutraceutical, food, confectionary, technical, and chemical products. The result is generations of experience developing the broadest, most innovative tableting equipment portfolio in the world. In operation worldwide, KORSCH tablet presses are supported by a global network of sales and technical service specialists.

About MEDELPHARM

Founded in 1985 in Lyon, France, MEDELPHARM has over 35 years of experience in the tableting sector. Among other initiatives, the precision engineering company designs and manufactures research & development compaction simulators, and provides innovative solutions for powder analysis and formulation support.

Staffed by a dedicated team of scientists and technicians, the MEDELPHARM Science Lab performs trials with predictive results and supports its customers with formulation and powder characterization challenges. In addition, MEDELPHARM Distribution also represents a range of solutions in powder processing, from R&D to production.

Previous Post

Fujifilm and the Center for Advanced Biological Innovation Announce 76 million USD in Funding for Manufacturing and Innovation Center

Next Post

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In